Advances in basic and preclinical science continue to fuel the drug discovery pipeline, however only a small fraction of compounds meet criteria for approval by the FDA.
Advances in basic and preclinical science continue to fuel the drug discovery pipeline, however only a small fraction of compounds meet criteria for approval by the FDA.